BridgeMD
New treatment option for Lung Cancer (Including Metastatic Cancer)
Official title Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study
ClinicalTrials.gov ID: NCT07339644
What this study is testing
- What it's testing
- This prospective, single-center, single-arm study will evaluate the feasibility and safety of 4DCT ventilation functional imaging-guided functional lung avoidance radiotherapy (FLAR) in patients with lung malignancies receiving IMRT radiotherapy. All participants will undergo 4DCT simulation as part of routine radiotherapy preparation.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Age 18 to 85 years (inclusive); any sex.
- Diagnosed lung malignancy requiring thoracic radiotherapy (e.g., non-small cell lung cancer, small cell lung cancer, or pulmonary metastases).
- Planned to receive thoracic radiotherapy using either conventionally fractionated IMRT/VMAT or stereotactic body radiotherapy (SBRT), and able to...
- Adequate baseline organ function and clinically judged able to tolerate radiotherapy; ECOG performance status 0-1.
- No absolute contraindication to pulmonary function testing; patients with moderate COPD or impaired lung function may be included if the treating...
You likely can't join if
- Pregnant or breastfeeding women. Women of childbearing potential must have pregnancy excluded prior to radiotherapy per institutional practice.
- Age \ 85 years.
- Uncontrolled severe cardiopulmonary disease or other severe comorbidities that make radiotherapy excessively high risk (e.g., decompensated heart...
- Prior high-dose thoracic radiotherapy to the same region such that safe re-irradiation is not feasible.
- Concurrent other active/advanced malignancy requiring priority treatment that would confound study outcomes.
- Recent participation in another treatment clinical trial or concurrent investigational therapy judged likely to interfere with this study's endpoints.
See the full eligibility criteria
- Age 18 to 85 years (inclusive); any sex.
- Diagnosed lung malignancy requiring thoracic radiotherapy (e.g., non-small cell lung cancer, small cell lung cancer, or pulmonary metastases).
- Planned to receive thoracic radiotherapy using either conventionally fractionated IMRT/VMAT or stereotactic body radiotherapy (SBRT), and able to complete pre-treatment 4DCT simulation suitable for generating a...
- Adequate baseline organ function and clinically judged able to tolerate radiotherapy; ECOG performance status 0-1.
- No absolute contraindication to pulmonary function testing; patients with moderate COPD or impaired lung function may be included if the treating team judges radiotherapy to be tolerable.
- Able to comply with treatment and follow-up assessments.
- Written informed consent provided.
- Pregnant or breastfeeding women. Women of childbearing potential must have pregnancy excluded prior to radiotherapy per institutional practice.
- Age \ 85 years.
- Uncontrolled severe cardiopulmonary disease or other severe comorbidities that make radiotherapy excessively high risk (e.g., decompensated heart failure, unstable cardiopulmonary status, active severe pulmonary...
- Prior high-dose thoracic radiotherapy to the same region such that safe re-irradiation is not feasible.
- Concurrent other active/advanced malignancy requiring priority treatment that would confound study outcomes.
- Recent participation in another treatment clinical trial or concurrent investigational therapy judged likely to interfere with this study's endpoints.
- Severe psychiatric, cognitive, or other conditions that prevent cooperation with radiotherapy and/or scheduled follow-up.
- Inadequate 4DCT image quality or inability to generate/validate the 4DCT ventilation map required for functional-lung-guided planning.
- Any other condition deemed unsuitable by the investigators in the interest of participant safety.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, China
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.